First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect
First-in-human study of the safety, pharmacokinetics, and
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and
Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant
Discovery of a mammalian FASN inhibitor against xenografts of non
Lost in FASN translation: from pre-clinical testing to first-in
Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP
Acetyl-CoA metabolism as a therapeutic target for cancer
Acetyl-CoA metabolism as a therapeutic target for cancer
FASN inhibitor TVB-3166 prevents S-acylation of the spike protein
Targeting fatty acid uptake and metabolism in cancer cells: A
Emerging roles of fatty acid metabolism in cancer and their
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640